A Phase I, Open-label Study of the Safety, Tolerability, and Pharmacokinetics of Oral Topotecan in Combination With Lapatinib in Subjects With Advanced Solid Tumors

Trial Profile

A Phase I, Open-label Study of the Safety, Tolerability, and Pharmacokinetics of Oral Topotecan in Combination With Lapatinib in Subjects With Advanced Solid Tumors

Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 25 Apr 2015

At a glance

  • Drugs Lapatinib (Primary) ; Topotecan (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 12 Mar 2010 Planned initiation date added to 1 Sep 2008 as reported by ClinicalTrials.gov.
    • 12 Mar 2010 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 15 Jan 2009 Planned initiation date changed from 1 Jun 2008 to 1 Sep 2008 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top